D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY TNFRSF13B/TACI and TNFRSF13C/BAFFR in B cell chronic lymphocytic leukemia.

Slides:



Advertisements
Similar presentations
Role of Vitamin D in Blood Malignancies Dr Imran Hilal.
Advertisements

BAFF and Autoimmune Disease
Targeted Therapies Against Lymphocyte Signaling Pathways in Childhood Leukemia Stuart S. Winter, MD Pediatric Hematology/Oncology The T. John Gribble Endowed.
Impact of HIV on Immunoglobulin Levels in CVID A primary immune deficiency Defined by hypogammaglobulinemia Males and females equally affected Many clinical.
Acute Myeloid Leukemia
Monoclonal antibodies Hybridoma Technique. Monoclonal antibodies (mAb or moAb) Monoclonal antibodies are:  monospecific antibodies that are identical.
LymphoStat-BTM A Case Study for Endpoints and Trial Design in SLE
Chronic Lymphocytic Leukemia. Definition Clonal B cell malignancy. Progressive accumulation of long lived mature lymphocytes. Increase in anti-apoptotic.
MONOCLONAL ANTIBODIES
G.Liguori,G.Pirozzi^, I. Forte, G.Botti, R.Franco, A.La Rocca*, G.Rocco* Istituto Nazionale Tumori Napoli Dip.Anatomia Patologica; Dip.Onc.Sperimentale^;
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Haematological Malignancy leukaemia and lymphoma,myeloma Concepts and principles Medical Students 2010.
Investigating Human T cells Using Multicolor Flow Cytometry Insoo Kang Section of Rheumatology.
AB CD T-cell Phenotypic Profile in Pregnancy: Link Between Immune Activation and Exhaustion N Shah 1, N Imami 1, M Johnson 1. 1 Imperial College London,
Research done by Dr. Jackleen Raafat Awadallah Hanna Phd of Medical Biochemistry Researcher at Medical Biochemistry Department National Research Center.
Lowhigh GSK3  P(S9)GSK3  CD38-APC CD45-Pacific BlueCD123-PE FSC CD34-PE-Cy7 SSC 0.3% A B C (X1000) (X1000) SSC 50.
Educational Presentation
EXPRESSION OF ILT3 RECEPTOR IN CHRONIC LYMPHOCYTIC LEUKEMIA Tyrone Reid HCS 2007 Mentor: Dr. Adrianna Colovai Columbia University Medical Center ( CUMC)
Ladies a gentlemen, Mr. Chairman
White blood cells and their disorders Dr K Hampton Haematologist Royal Hallamshire Hospital.
Slideset on: Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the.
B Cell Activation Abul K. Abbas UCSF FOCiS.
Paige Myers & Mahek Shah.  Cancer is a disease in which the DNA of cells becomes damaged or changed and the affected cells do not respond to apoptosis.
Low Grade Lymphomas: Treatment approaches Parameswaran Venugopal, MD Professor of Medicine Rush University Medical Center.
Lactate dehydrogenase is crucial for tumor associated macrophage protection of multiple myeloma cells against chemotherapy Carolyn Stierhoff, Enguang Bi,
Biomarkers for personalized therapy in myeloma
Rationale, aim and conculsion
Vasopressin and noradrenaline reduce LPS-induced monocyte TNF release
TNF-like weak inducer of apoptosis (TWEAK) and TNF-α cooperate in the induction of keratinocyte apoptosis  Maya Zimmermann, PhD, Andrea Koreck, MD, Norbert.
B-cell receptor signaling in chronic lymphocytic leukemia
Reduced number of peripheral natural killer cells in schizophrenia but not in bipolar disorder – a computational deconvolution study Paweł Karpiński1,
Discussion and Conclusions Acknowledgements and References
Chronic immune activation in HIV associated Non Hodgkin lymphoma and the effect of antiretroviral therapy Brian Flepisi University of the Western Cape.
Immunology Ch Microbiology.
chimeric antigen receptor T-cell therapy for ALL
Prot eins Immune Checkpoint. CONTENTS Page 3 Immune System Page 7 Cancer and Immune Response Page 9 Immuno-Oncology Page 12 Immune Checkpoint Proteins.
Memory B cells IgM only Marginal zone B cells without plasmablasts
IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity.
Immunotherapy for lymphoma: The time is now
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival by Kai-Da Wu, Lisa.
Chronic Leukemia Kristine Krafts, M.D..
The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages by Barbara Scheuerer, Martin Ernst,
Multiple myeloma (MM) & related disorders
Figure 1 Targets for monoclonal antibodies in B-cell lineages
Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes
Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation by Shiguo Zhu, Prasad V. Phatarpekar,
Increased survival is a selective feature of human circulating antigen-induced plasma cells synthesizing high-affinity antibodies by Inés González-García,
Role of IL-9 in the pathophysiology of allergic diseases
Chronic neutropenia mediated by Fas ligand
TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow by Shoichiro Tsuji, Catarina Cortesão,
Multiple Myeloma Overview all transplants, autologous and allogeneic (period ) N=28.887
LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis by Albert Gutierrez,
The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia by Christine Le Roy, Pierre-Antoine Deglesne, Nathalie.
Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach  Jeremiah.
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT by Akil A. Merchant, Aparna Jorapur, Amy McManus, Ren Liu, Valery Krasnoperov,
Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia by Shahrzad Jalali, Tammy Price-Troska, Jonas Paludo, Jose Villasboas, Hyo-Jin.
Volume 18, Issue 2, Pages (February 2003)
FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.
L’antagoniste se lie à Blys
by Kamira Maharaj, John J
LRBA protein expression in lymphocytes from a healthy individual and a patient. LRBA protein expression in lymphocytes from a healthy individual and a.
Volume 24, Issue 9, Pages (September 2016)
Lymphoma in Pediatrics 23rd Nov 2018
Characterization of ζ-associated protein, 70 kd (ZAP70)–deficient human lymphocytes  Chaim M. Roifman, MD, Harjit Dadi, PhD, Raz Somech, MD, Amit Nahum,
Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies by Nadine Müller-Calleja, Svenja.
Monoclonal antibodies and fusion proteins and their complications: Targeting B cells in autoimmune diseases  Susan Lee, MD, Mark Ballow, MD  Journal of.
Flow cytometric gating strategy used to identify CD69 surface expression on CD4 (left paired columns) and CD8 (right paired columns) T lymphocytes. Flow.
Presentation transcript:

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY TNFRSF13B/TACI and TNFRSF13C/BAFFR in B cell chronic lymphocytic leukemia

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY Introduction TACI: Receptor of BAFF and APRIL participates in: Survival and differentiation of B cells T cell-independent immune respon- ses Antibody production Isotype switching Homeostasis of B cells BAFF-R: Receptor of BAFF Expressed on naïve B cells triggering their survival and maturation Mackay et al, Cytokines & Growth Factor Reviews 2008

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY Novak et al, Blood 2002 Hait et al., Immunology 2006 Jian et al., Medical Journal 2008 TACI and BAFFR might participate in the survival of B-CLL cells, protecting them from apoptosis through NFκΒ activation Introduction

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY Anti-TACI, anti-BAFF and anti-APRIL therapeutic approaches are now available, for the treatment of patients with autoimmune diseases and might be useful in patients with B-CLL Phase I/II study of TACI-Ig to neutralize APRIL and BlyS (R) in patients with refractory or relapsed multiple myeloma or active previously-treated Waldenstrom’s macroglobuliemia. Rossi et al, Blood 2005 Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Lee et al, Blood 2006 Phase I clinical study of Atacicept in patients with relapsed and refractory B-cell Non- Hodgkin’s Lymphoma. Ansell et al, Clin Cancer Res, 2008 Ib trial of Atacicept, a recombinant protein binding BlyS and APRIL, in patients with chronic lymphocytic leukemia (B-CLL) Kofler et al, Leukemia 2011 Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Guadagnoli et al, Blood 2011 Introduction

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY The determination of TNFRSF13B/ TACI and TNFRSF13C/ BAFFR expression on B-CLL cells and their contribution to the phenotype and the prognosis of the disease Aim of the study

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY Bone marrow 104 patients with B-CLL (M/F: 59/45, mean age: 68.5 y) 30 patients with low-grade NHL (M/F: 18/12, mean age: 77.3 y) & 145 healthy donors (M/F: 84/61, mean age: 67.8 y) Peripheral blood Materials & Methods

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY 1.Hematologic, serologic and flow cytometric analyses (for diagnostic purposes), including in B-CLL a further analysis of the most powerful prognostic factors (ZAP-70, CD38 and IgH mutational status). 2.TACI and BAFFR protein expression was detected by flow cytometry using monoclonal antibodies (TACI clone 1a1, Abcam and BAFFR clone 11C1 Biolegend, respectively) in all samples. 3.TNFRSF13B and TNFRSF13C mRNA expression were estimated by qRT-PCR in 29 samples (19 with B-CLL, 8 with NHL and isolated B cells from 2 healthy donors). Materials & Methods

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY Materials & Methods 4.B-CLL cells exhibiting high or absent TACI, were stimulated by PKW (pokweed) 2.5 ng/mL, BAFF 1 μg/mL and APRIL 200 ng/mL and the apoptosis status was estimated by flow cytometry using an Annexin V-FITC/ 7-AAD (7-AAD) kit. 5.BAFF and APRIL serum levels were estimated by ELISA in 37 samples (16 with B-CLL, 11 with NHL and 10 healthy donors). 6.The statistical analysis was performed using the SPSS software ver.16.0.

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY Results - 1 TACI=2.1% TACI=55%TACI=90.1% Variable TACI mRNA and protein expression on B-CLL cells BAFFR protein expression B-CLL cells normal B cells MFI=6 MFI=11

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY Results - 2 TACI=2.1% TACI=55%TACI=90.1% Variable TACI mRNA and protein expression on B-CLL cells TACI mean expression ± STDEV B-CLL patients 13.4 ± 22%p < 0.05 NHL patients 36.8 ± 29%p = Healthy donors 27.6 ± 14.2% B-CLL NHL Healthy TACI expression (%)

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY TACI expression was not asso-ciated with (p>0.05) : the presence of autoimmunity, hypogammaglobulinemia, monoclonal gammapathy, the infection risk and the known prognostic factors of B-CLL Results - 3 PtsDiseaseTACI (%)Hypermutation status(%) CD38 (%) 1.B-CLL B-NHL B-CLL B-CLL B-CLL B-CLL B-CLL B-CLL B-CLL B-CLL B-CLL B-NHL84886 Low TACI Medium TACI High TACI hypermutation status ≤ 98% good prognosis CD38 > 20% bad prognosis

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY CONTROLBAFFAPRIL CONTROLBAFF TACI protects B-CLL cells from apoptosis TACI=2.1% TACI=50.1% aliveEarly apoptotic Late apoptotic&dead aliveEarly apoptotic Late apoptotic&dead aliveEarly apoptotic Late apoptotic&dead aliveEarly apoptotic Late apoptotic&dead aliveEarly apoptotic Late apoptotic&dead aliveEarly apoptotic Late apoptotic&dead Results - 4

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY B-CLL NHL Healthy BAFFR_MFI Mean ± STDEV B-CLL patients 6.71 ± 2.9%p < 0.05 NHL patients 6.7 ± 3.7%p = 0.05 Healthy donors 10.7 ± 5.9% BCLL cells Normal B cells At the relapse of the disease Results - 5

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY Serum BAFF was low and APRIL high in the majority of B-CLL patients compared to NHL patients and healthy donors BAFF pg/ml Median (Range) APRIL pg/ml Median (Range) B-CLL patients0 (0 – 55.0)5.11 ( ) NHL patients 9.0 (0 – 152.0)2.21 ( ) Healthy donors49.5 (21.8 – 92.0)4.78 ( ) Soluble BAFF levels was low to undetectable in B-CLL patients. Kreuzaler et al, J Immunol 2012 APRIL serum levels predict time to first treatment in patients affected by B- cell chronic lymphocytic leukemia. Tecchio et al, Eur. J. Haematol 2011 Results - 6

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY Conclusions TACI expression is: low in the majority of B-CLL patients not associated with disease prognosis accompanied by very low or absent serum BAFF and high serum APRIL levels BAFFR MFI expression is: low in the B-CLL and NHL patients These findings should be taken into account in the case of anti- TACI and anti-BAFFR therapeutic approaches.

D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY THANK YOU